- Home
- BSIN vs VERU Comparison
BSIN vs VERU Comparison
Compare BSIN & VERU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | BSIN | VERU |
|---|---|---|
| Founded | N/A | 1971 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Oil & Gas Production | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 53.4M | 44.0M |
| IPO Year | 1995 | 1996 |
Fundamental Metrics
Financial Performance| Metric | BSIN | VERU |
|---|---|---|
| Price | $1.56 | $2.45 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $22.50 |
| AVG Volume (30 Days) | ★ 873.7K | 199.1K |
| Earning Date | N/A | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 55.21 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $32,379,000.00 | $16,296,958.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $1.00 | $2.05 |
| 52 Week High | $1.65 | $7.33 |
Technical Indicators
Market Signals| Indicator | BSIN | VERU |
|---|---|---|
| Relative Strength Index (RSI) | 69.73 | 43.35 |
| Support Level | $1.40 | $2.12 |
| Resistance Level | N/A | $2.67 |
| Average True Range (ATR) | 0.08 | 0.14 |
| MACD | 0.00 | -0.03 |
| Stochastic Oscillator | 92.98 | 5.14 |
Price Performance
Historical ComparisonAbout VERU Veru Inc.
Veru Inc is a late clinical-stage biopharmaceutical focused on developing medicines for the treatment of cardiometabolic and inflammatory diseases. Its drug development program consists of two late-stage new chemical entities, enobosarm and sabizabulin. Enobosarm, an oral selective androgen receptor modulator, is being developed to make weight reduction by GLP-1 RA drugs more tissue selective for loss of fat and preservation of lean mass, and is planned for a Phase 2b PLATEAU clinical study in obesity. Sabizabulin, an oral microtubule disruptor, is being developed for the treatment of inflammation in atherosclerotic cardiovascular disease to lower high-sensitivity CRP in patients with stable coronary artery disease, with a planned Phase 2 study.